That’s the problem... management isn’t telling us what was contained within the refusal to file letter they received from the FDA. It is not the FDA‘s responsibility to inform shareholders As to its communication with the company its managements responsibility. NP knows what the problem is and we don’t. Is it receptor occupancy data that’s missing? Is it stability data in the syringe? Is it a manufacturing deficiency? The point is we have no clue because it hasn’t been conveyed to us in a clear concise message from management.
How are you supposed to make investment decisions when you don’t have all the information and the person tasked with a fiduciary responsibility of conveying that information to you is being deliberately evasive.
Market Data 
Markets 
AI
